155 related articles for article (PubMed ID: 26968647)
1. Design and synthesis of small molecule-sulfotyrosine mimetics that inhibit HIV-1 entry.
Dogo-Isonagie C; Lee SL; Lohith K; Liu H; Mandadapu SR; Lusvarghi S; O'Connor RD; Bewley CA
Bioorg Med Chem; 2016 Apr; 24(8):1718-28. PubMed ID: 26968647
[TBL] [Abstract][Full Text] [Related]
2. Structure-based identification and neutralization mechanism of tyrosine sulfate mimetics that inhibit HIV-1 entry.
Acharya P; Dogo-Isonagie C; LaLonde JM; Lam SN; Leslie GJ; Louder MK; Frye LL; Debnath AK; Greenwood JR; Luongo TS; Martin L; Watts KS; Hoxie JA; Mascola JR; Bewley CA; Kwong PD
ACS Chem Biol; 2011 Oct; 6(10):1069-77. PubMed ID: 21793507
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine-sulfated V2 peptides inhibit HIV-1 infection via coreceptor mimicry.
Cimbro R; Peterson FC; Liu Q; Guzzo C; Zhang P; Miao H; Van Ryk D; Ambroggio X; Hurt DE; De Gioia L; Volkman BF; Dolan MA; Lusso P
EBioMedicine; 2016 Aug; 10():45-54. PubMed ID: 27389109
[TBL] [Abstract][Full Text] [Related]
4. Reversible and efficient activation of HIV-1 cell entry by a tyrosine-sulfated peptide dissects endocytic entry and inhibitor mechanisms.
Platt EJ; Gomes MM; Kabat D
J Virol; 2014 Apr; 88(8):4304-18. PubMed ID: 24478426
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine-sulfate isosteres of CCR5 N-terminus as tools for studying HIV-1 entry.
Lam SN; Acharya P; Wyatt R; Kwong PD; Bewley CA
Bioorg Med Chem; 2008 Dec; 16(23):10113-20. PubMed ID: 18952441
[TBL] [Abstract][Full Text] [Related]
6. A tyrosine-sulfated peptide based on the N terminus of CCR5 interacts with a CD4-enhanced epitope of the HIV-1 gp120 envelope glycoprotein and inhibits HIV-1 entry.
Farzan M; Vasilieva N; Schnitzler CE; Chung S; Robinson J; Gerard NP; Gerard C; Choe H; Sodroski J
J Biol Chem; 2000 Oct; 275(43):33516-21. PubMed ID: 10938094
[TBL] [Abstract][Full Text] [Related]
7. Activation and Inactivation of Primary Human Immunodeficiency Virus Envelope Glycoprotein Trimers by CD4-Mimetic Compounds.
Madani N; Princiotto AM; Zhao C; Jahanbakhshsefidi F; Mertens M; Herschhorn A; Melillo B; Smith AB; Sodroski J
J Virol; 2017 Feb; 91(3):. PubMed ID: 27881646
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, Antiviral Potency, in Vitro ADMET, and X-ray Structure of Potent CD4 Mimics as Entry Inhibitors That Target the Phe43 Cavity of HIV-1 gp120.
Curreli F; Kwon YD; Belov DS; Ramesh RR; Kurkin AV; Altieri A; Kwong PD; Debnath AK
J Med Chem; 2017 Apr; 60(7):3124-3153. PubMed ID: 28266845
[TBL] [Abstract][Full Text] [Related]
9. A double-mimetic peptide efficiently neutralizes HIV-1 by bridging the CD4- and coreceptor-binding sites of gp120.
Quinlan BD; Joshi VR; Gardner MR; Ebrahimi KH; Farzan M
J Virol; 2014 Mar; 88(6):3353-8. PubMed ID: 24390333
[TBL] [Abstract][Full Text] [Related]
10. Sulfotyrosine dipeptide: Synthesis and evaluation as HIV-entry inhibitor.
Ju T; Hu D; Xiang SH; Guo J
Bioorg Chem; 2016 Oct; 68():105-11. PubMed ID: 27475281
[TBL] [Abstract][Full Text] [Related]
11. In Silico Identification of Novel Aromatic Compounds as Potential HIV-1 Entry Inhibitors Mimicking Cellular Receptor CD4.
Andrianov AM; Nikolaev GI; Kornoushenko YV; Xu W; Jiang S; Tuzikov AV
Viruses; 2019 Aug; 11(8):. PubMed ID: 31412617
[TBL] [Abstract][Full Text] [Related]
12. Peptides from second extracellular loop of C-C chemokine receptor type 5 (CCR5) inhibit diverse strains of HIV-1.
Dogo-Isonagie C; Lam S; Gustchina E; Acharya P; Yang Y; Shahzad-ul-Hussan S; Clore GM; Kwong PD; Bewley CA
J Biol Chem; 2012 Apr; 287(18):15076-86. PubMed ID: 22403408
[TBL] [Abstract][Full Text] [Related]
13. Binding thermodynamics of the N-terminal peptide of the CCR5 coreceptor to HIV-1 envelope glycoprotein gp120.
Brower ET; Schön A; Klein JC; Freire E
Biochemistry; 2009 Feb; 48(4):779-85. PubMed ID: 19170639
[TBL] [Abstract][Full Text] [Related]
14. Small-Molecule CD4 Mimics Containing Mono-cyclohexyl Moieties as HIV Entry Inhibitors.
Ohashi N; Harada S; Mizuguchi T; Irahara Y; Yamada Y; Kotani M; Nomura W; Matsushita S; Yoshimura K; Tamamura H
ChemMedChem; 2016 Apr; 11(8):940-6. PubMed ID: 26891461
[TBL] [Abstract][Full Text] [Related]
15. Design of gp120 HIV-1 entry inhibitors by scaffold hopping via isosteric replacements.
Iusupov IR; Curreli F; Spiridonov EA; Markov PO; Ahmed S; Belov DS; Manasova EV; Altieri A; Kurkin AV; Debnath AK
Eur J Med Chem; 2021 Nov; 224():113681. PubMed ID: 34246921
[TBL] [Abstract][Full Text] [Related]
16. A tyrosine-sulfated peptide derived from the heavy-chain CDR3 region of an HIV-1-neutralizing antibody binds gp120 and inhibits HIV-1 infection.
Dorfman T; Moore MJ; Guth AC; Choe H; Farzan M
J Biol Chem; 2006 Sep; 281(39):28529-35. PubMed ID: 16849323
[TBL] [Abstract][Full Text] [Related]
17. A low-molecular-weight entry inhibitor of both CCR5- and CXCR4-tropic strains of human immunodeficiency virus type 1 targets a novel site on gp41.
Murray EJ; Leaman DP; Pawa N; Perkins H; Pickford C; Perros M; Zwick MB; Butler SL
J Virol; 2010 Jul; 84(14):7288-99. PubMed ID: 20427524
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and evaluation of HIV-1 entry inhibitors based on broadly neutralizing antibody 447-52D and gp120 V3loop interactions.
Senapathi J; Bommakanti A; Vangara S; Kondapi AK
Bioorg Chem; 2021 Nov; 116():105313. PubMed ID: 34517280
[TBL] [Abstract][Full Text] [Related]
19. A novel small-molecule inhibitor of HIV-1 entry.
Heredia A; Latinovic OS; Barbault F; de Leeuw EP
Drug Des Devel Ther; 2015; 9():5469-78. PubMed ID: 26491257
[TBL] [Abstract][Full Text] [Related]
20. A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations.
Roche M; Salimi H; Duncan R; Wilkinson BL; Chikere K; Moore MS; Webb NE; Zappi H; Sterjovski J; Flynn JK; Ellett A; Gray LR; Lee B; Jubb B; Westby M; Ramsland PA; Lewin SR; Payne RJ; Churchill MJ; Gorry PR
Retrovirology; 2013 Apr; 10():43. PubMed ID: 23602046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
